Literature DB >> 20507316

Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease.

Juliette Berger1, Séverine Lecourt, Valérie Vanneaux, Chantal Rapatel, Stéphane Boisgard, Catherine Caillaud, Nathalie Boiret-Dupré, Christine Chomienne, Jean-Pierre Marolleau, Jérôme Larghero, Marc G Berger.   

Abstract

One of the cardinal symptoms of type 1 Gaucher Disease (GD) is cytopenia, usually explained by bone marrow (BM) infiltration by Gaucher cells and hypersplenism. However, some cases of cytopenia in splenectomized or treated patients suggest possible other mechanisms. To evaluate intra-cellular glucocerebrosidase (GlcC) activity in immature progenitors and to prove the conduritol B epoxide (CBE)-induced inhibition of the enzyme, we used an adapted flow cytometric technique before assessing the direct effect of GlcC deficiency in functional assays. Among haematopoietic cells from healthy donors, monocytes showed the highest GlcC activity but immature CD34(+) and mesenchymal cells also had significant GlcC activity. CBE greatly inhibited the enzyme activity of all cell categories. GlcC-deficient CD34(+) cells showed impaired ability to proliferate and differentiate in the expansion assay and had lower frequency of erythroid burst-forming units, granulocyte colony-forming units (CFU) and macrophage CFU progenitors, but the effect of GlcC deficiency on megakaryocyte CFU lineage was not significant. GlcC deficiency strongly impaired primitive haematopoiesis in long-term culture. Furthermore, GlcC deficiency progressively impaired proliferation of mesenchymal progenitors. These data suggest an intrinsic effect of GlcC deficiency on BM immature cells that supplements the pathophysiology of GD and opens new perspectives of therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20507316     DOI: 10.1111/j.1365-2141.2010.08214.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Gaucher disease gene GBA functions in immune regulation.

Authors:  Jun Liu; Stephanie Halene; Mei Yang; Jameel Iqbal; Ruhua Yang; Wajahat Z Mehal; Wei-Lien Chuang; Dhanpat Jain; Tony Yuen; Li Sun; Mone Zaidi; Pramod K Mistry
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

Review 2.  Measuring enzyme activity in single cells.

Authors:  Michelle L Kovarik; Nancy L Allbritton
Journal:  Trends Biotechnol       Date:  2011-02-11       Impact factor: 19.536

3.  Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis.

Authors:  Judi A Sgambato; Tea Soon Park; Diana Miller; Leelamma M Panicker; Ellen Sidransky; Yu Lun; Ola Awad; Søren M Bentzen; Elias T Zambidis; Ricardo A Feldman
Journal:  Stem Cells Transl Med       Date:  2015-06-10       Impact factor: 6.940

Review 4.  Gaucher disease.

Authors:  Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

5.  Unexpected macrophage-independent dyserythropoiesis in Gaucher disease.

Authors:  Nelly Reihani; Jean-Benoit Arlet; Michael Dussiot; Thierry Billette de Villemeur; Nadia Belmatoug; Christian Rose; Yves Colin-Aronovicz; Olivier Hermine; Caroline Le Van Kim; Melanie Franco
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

6.  Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.

Authors:  Juliette Berger; Marie Vigan; Bruno Pereira; Thu Thuy Nguyen; Roseline Froissart; Nadia Belmatoug; Florence Dalbiès; Agathe Masseau; Christian Rose; Christine Serratrice; Yves-Marie Pers; Ivan Bertchansky; Fabrice Camou; Monia Bengherbia; Céline Bourgne; Catherine Caillaud; Magali Pettazzoni; Amina Berrahal; Jérôme Stirnemann; France Mentré; Marc G Berger
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

7.  Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity.

Authors:  Philip Stein; Ruhua Yang; Jun Liu; Gregory M Pastores; Pramod K Mistry
Journal:  J Inherit Metab Dis       Date:  2011-02-03       Impact factor: 4.982

Review 8.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Fabrice Camou; Christine Serratrice; Roseline Froissart; Catherine Caillaud; Thierry Levade; Leonardo Astudillo; Jacques Serratrice; Anaïs Brassier; Christian Rose; Thierry Billette de Villemeur; Marc G Berger
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

9.  A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients.

Authors:  Séverine Lecourt; Enguerran Mouly; Delphine Freida; Audrey Cras; Raphaël Ceccaldi; Djazia Heraoui; Christine Chomienne; Jean-Pierre Marolleau; Bertrand Arnulf; Raphael Porcher; Catherine Caillaud; Valérie Vanneaux; Nadia Belmatoug; Jérôme Larghero
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

10.  Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease.

Authors:  Farzaneh Atashrazm; Deborah Hammond; Gayathri Perera; Carol Dobson-Stone; Nicole Mueller; Russell Pickford; Woojin Scott Kim; John B Kwok; Simon J G Lewis; Glenda M Halliday; Nicolas Dzamko
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.